Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nymox Reports Positive Results For NX-1207
Nymox Pharmaceuticals (Nymox) has reported positive and repeatable results for NX-1207 in laboratory studies of human prostate cancer. In addition, local injection of NX-1207 has showed activity in
Nymox Pharmaceuticals (Nymox) has reported positive and repeatable results for NX-1207 in laboratory studies of human prostate cancer. In addition, local injection of NX-1207 has showed activity in
Serametrix has partnered with the Ludwig Institute for Cancer Research (LICR). The agreement will combine LICR’s discoveries in tumor immunology with the technologies and commercial capabilities of Serametrix.
Ortho Clinical Diagnostics (Ortho) has received FDA approval for Anti-HIV 1+2. Its a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV
The company will also demo four new products that are expected to be launched in the next few quarters, which include: In-Vitro Diagnostic Products – BC-5800 five-part hematology
Generex Biotechnology (Generex) has received FDA price approval for the use of Oral-lyn under the FDA’s Treatment Investigational New Drug (IND) program. The company has previously said that
pSivida has reported that the last patient in the phase III clinical trial being conducted by its collaborative partner, Alimera Sciences (for a new treatment for diabetic macular
Fero Industries has entered into an agreement to acquire Pyro Pharmaceuticals of Irvine, California. Pyro develops therapeutics against multi-drug resistant infectious microorganisms. Pyro’s focus is on diseases in
The European Medicines Evaluation Agency (EMEA) has given orphan drug status to ARQ 197, a treatment for Soft Tissue Sarcoma. Medicinal products are designated as orphan drugs by
ZyStor Therapeutics (ZyStor) has received clearance from the FDA to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment
Fueled by strong sales of its rheumatoid arthritis drug Humira and nutritional products, Abbott Labs has reported net earnings of $1.48 billion for the third quarter of 2009,